Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:13:24.519Z.
Calculation as of: 2026-10-06T22:13:24.519Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 717d9e1ca299c0a9e32b76938e5c8cfcb507e231e4f72cb05b36dcb8f57dd66d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$5.92M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.82M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.58M
EV/EBIT Ratio
N/A
TTM Avg
1748.82x
3Y Avg
1748.82x
5Y Avg
1748.82x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | $6.11M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | N/A | N/A | N/A | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | N/A | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.83M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 1748.82x | 1748.82x | 1748.82x |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
